The Parker Institute for Cancer Immunotherapy, a network of the largest concentration of immuno-oncology expertise in the world, has added Dana-Farber Cancer Institute and Gladstone Institutes to its network of academic and medical research institutions.
The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.
